Taysha Gene Therapies Net Profit Margin 2020-2024 | TSHA

Taysha Gene Therapies net profit margin from 2020 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Taysha Gene Therapies Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-09-30 $0.01B $-0.02B -230.00%
2024-06-30 $0.01B $-0.11B -876.92%
2024-03-31 $0.01B $-0.12B -842.86%
2023-12-31 $0.02B $-0.11B -700.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00